LemonBox Health

-13%

est. 2Y upside i

HealthcareSeries A

From vitamins to meals, AI that optimizes your daily nutrition.

Rank

#2621

Sector

Health Technology

Est. Liquidity

~3Y

Data Quality

Data: Low

Expected negative return of -13% over 2 years, with low confidence due to missing data.

Last updated: July 19, 2026

Bull (15%)+93%

If IPO window opens and multiples expand to 4x, exit value reaches $48M. But dilution reduces net upside to 93%.

Base (55%)-13%

Moderate growth leads to 2x multiple, exit value $24M. After dilution, net return is -13%.

Bear (30%)-67%

Multiple compresses to 1x, exit value $12M. Dilution and low valuation result in severe loss for common equity.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Funding Intensity

2000%

Total funding of $4.5M represents 20% of estimated entry valuation, creating high preference overhang.

Dilution Risk

high

No new round in over 4 years suggests a raise is likely, diluting existing common shareholders by ~20%.

Secondary Liquidity

none

No secondary market data available; liquidity is likely limited to an IPO or M&A.

Questions to Ask at the Interview

Strategic questions based on LemonBox Health's data — designed to show you've done your homework.

1
“What is your strategy for overcoming regulatory hurdles for imported supplements in China?”
2
“How do you plan to achieve profitability given your gross margin of 50%?”
3
“What is the expected timeline for a liquidity event (IPO or acquisition)?”

Our model estimates -13% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.